Use of cisplatin for treatment of appendicular osteosarcoma in dogs.
Nineteen dogs were treated for osteosarcoma of the appendicular skeleton. Eleven dogs treated by amputation and adjunctive cisplatin chemotherapy had a significantly longer (P less than 0.003) median survival time of 43 weeks (range, 20 to 108 weeks) than did 8 dogs whose median survival time was 14.5 weeks (range, 8 to 46 weeks) after amputation alone. All 11 dogs given cisplatin were evaluated for signs of drug toxicosis. Transient episodes of vomiting were recorded in 9 of 11 dogs. Additional toxic effects included gradual decreases in endogenous creatinine clearance in 3 dogs and thrombocytopenia in 1 dog. On the basis of prolonged survival times and minimal adverse effects, we concluded that cisplatin has promise as an effective and relatively nontoxic agent, when combined with amputation, for treatment of dogs with osteosarcoma of the appendicular skeleton.
Shapiro
W
W
Clinical Oncology Section, Veterinary Medical Teaching Hospital, School of Veterinary Medicine, University of California, Davis 95616.
Fossum
T W
TW
Kitchell
B E
BE
Couto
C G
CG
Theilen
G H
GH
D000671:Amputation, Surgical / Q000662:veterinary; D000818:Animals; D001859:Bone Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000662:veterinary*; D002945:Cisplatin / Q000627:therapeutic use*; D004283:Dog Diseases / Q000188:drug therapy* / Q000601:surgery; D004285:Dogs; D005121:Extremities; D005260:Female; D008297:Male; D012516:Osteosarcoma / Q000188:drug therapy / Q000601:surgery / Q000662:veterinary*
D002945:Cisplatin